Traders Sell Shares of Becton, Dickinson and (BDX) on Strength (BDX)

Investors sold shares of Becton, Dickinson and Company (NYSE:BDX) on strength during trading on Tuesday. $57.99 million flowed into the stock on the tick-up and $96.93 million flowed out of the stock on the tick-down, for a money net flow of $38.94 million out of the stock. Of all companies tracked, Becton, Dickinson and had the 0th highest net out-flow for the day. Becton, Dickinson and traded up $0.68 for the day and closed at $218.99

Several research firms have recently issued reports on BDX. Stifel Nicolaus reissued a “buy” rating and issued a $245.00 price objective on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Royal Bank of Canada reissued a “sector perform” rating and issued a $230.00 price objective (up previously from $210.00) on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Morgan Stanley increased their price objective on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Argus raised their price target on shares of Becton, Dickinson and to $235.00 and gave the company a “buy” rating in a report on Thursday. They noted that the move was a valuation call. Finally, Wells Fargo & Company reaffirmed a “positive” rating and set a $235.00 price target (up from $225.00) on shares of Becton, Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Becton, Dickinson and has a consensus rating of “Buy” and an average price target of $218.36.

The stock has a market capitalization of $49,910.00, a price-to-earnings ratio of 23.08, a price-to-earnings-growth ratio of 1.71 and a beta of 1.06. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The business’s revenue was down 2.0% on a year-over-year basis. During the same period last year, the business earned $2.12 EPS. sell-side analysts predict that Becton, Dickinson and Company will post 10.63 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be paid a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.37%. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date of this dividend is Thursday, December 7th. Becton, Dickinson and’s dividend payout ratio is 64.52%.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Becton, Dickinson and by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after acquiring an additional 1,353,780 shares during the last quarter. State Street Corp boosted its stake in Becton, Dickinson and by 3.5% during the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after acquiring an additional 342,873 shares during the last quarter. Northern Trust Corp boosted its stake in Becton, Dickinson and by 4.0% during the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock valued at $549,028,000 after acquiring an additional 106,966 shares during the last quarter. Fiera Capital Corp boosted its stake in Becton, Dickinson and by 7.1% during the 2nd quarter. Fiera Capital Corp now owns 2,782,146 shares of the medical instruments supplier’s stock valued at $542,825,000 after acquiring an additional 183,372 shares during the last quarter. Finally, Fundsmith LLP boosted its stake in Becton, Dickinson and by 0.3% during the 2nd quarter. Fundsmith LLP now owns 2,302,590 shares of the medical instruments supplier’s stock valued at $449,258,000 after acquiring an additional 5,977 shares during the last quarter. Hedge funds and other institutional investors own 88.60% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2017/12/14/traders-sell-shares-of-becton-dickinson-and-bdx-on-strength-bdx.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply